Bevacizumab (Avastin)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Monoclonal antibody that inhibits angiogenesis by binding VEGF and preventing the interaction of VEGF with its receptors (Flt-1 and KDR) on the surface of endothelial cells.[1][2][3]
Route: IV
Extravasation: neutral

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Information about counterfeit bevacizumab

Patient drug information

History of changes in FDA indication

Also known as

  • Generic name: rhuMab-VEGF
  • Brand names: Altuzan, Avastin, BevaciRel, Bevarest

References

  1. 1.0 1.1 1.2 Bevacizumab (Avastin) package insert
  2. Bevacizumab (Avastin) package insert (locally hosted backup)
  3. Avastin manufacturer's website
  4. Bevacizumab (Avastin) patient drug information (Chemocare)
  5. Bevacizumab (Avastin) patient drug information (UpToDate)